KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Intangibles (2021 - 2026)

Pacific Biosciences Of California has reported Intangibles over the past 5 years, most recently at $15.1 million for Q4 2025.

  • For Q4 2025, Intangibles fell 96.12% year-over-year to $15.1 million; the TTM value through Dec 2025 reached $15.1 million, down 96.12%, while the annual FY2025 figure was $15.1 million, 96.12% down from the prior year.
  • Intangibles for Q4 2025 was $15.1 million at Pacific Biosciences Of California, down from $16.1 million in the prior quarter.
  • Over five years, Intangibles peaked at $461.8 million in Q3 2023 and troughed at $15.1 million in Q4 2025.
  • A 5-year average of $332.1 million and a median of $410.3 million in 2022 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: grew 12.56% in 2023 and later crashed 96.3% in 2025.
  • Year by year, Intangibles stood at $411.0 million in 2021, then dropped by 0.18% to $410.2 million in 2022, then increased by 11.39% to $457.0 million in 2023, then decreased by 14.75% to $389.6 million in 2024, then crashed by 96.12% to $15.1 million in 2025.
  • Business Quant data shows Intangibles for PACB at $15.1 million in Q4 2025, $16.1 million in Q3 2025, and $17.2 million in Q2 2025.